Stock disconnect triggers investor exodus from CStone Pharma
The share price fell nearly 40% in a week after the drugs company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks Key Takeaways: CEO Jason…
Everest reaches new heights on growing drug sales
The innovative drug maker said its revenue soared more than 850% last year to between 124 million yuan and 126 million yuan Key Takeaways: Everest Medicines’ revenue soared nine-fold last…
Zai Lab sees profits on the horizon as commercialization accelerates
The innovative drug maker’s loss narrowed last year, as it forecast potential profitability as soon as 2025 on fast-growing revenues Key Takeaways: Zai Lab is set to reach several product…
FAST NEWS: Zai Lab’s Loss Narrows as Core Products Post Strong Growth
The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) on Wednesday reported a $137.9 million net loss in the second quarter, 15.4% narrower than its $163 million loss a year earlier. Looking…
RELATED ARTICLES
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Hong Kong’s Café de Coral takes go-slow approach to Mainland dining market
0341.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
CIMC Vehicles heads for Hong Kong exit ramp via share buyback
1839.HK 301039.SHE
- Charged up by new investor BYD, BaTeLab cleared for IPO
